MedTrace Logo

Bioavailability of Hydroxytyrosol in Humans Co-administered With EPA

NCT06735222 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-04-11

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the optimal formulation of a natural nutraceutical whose daily consumption at nutritional doses may confer benefits for cardiovascular health. This nutraceutical combines an omega-3 fatty acid (eicosapentaenoic acid, EPA) with hydroxytyrosol (a potent antioxidant found in olives and extra virgin olive oil). The study will allow to compare how and to what extent hydroxytyrosol is absorbed when co-administered the omega-3 fatty acid in capsules across three different formulations.

Conditions

  • Healthy
  • Young

Interventions

DIETARY_SUPPLEMENT

Hydroxytyrosol acetate (HT-Ac)

Hydroxytyrosol acetate (15 mg) orally co-administered with 2 g EPA

DIETARY_SUPPLEMENT

Hydroxytyrosol eicosapentanoate (HT-EPA)

Oral intake of hydroxytyrosol eicosapentanoate (15 mg) solubilized in an EPA-enriched oil matrix.

DIETARY_SUPPLEMENT

Oleacore®

Oleacore® (containing 15 mg of hydroxytyrosol) orally co-administered with 2 g EPA

Sponsors & Collaborators

  • Olivenova Health Sl

    collaborator UNKNOWN

  • National Research Council, Spain

    lead OTHER_GOV

Principal Investigators

  • Raquel Mateos Briz Tenured Scientist · 1

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-18
Primary Completion
2024-12-04
Completion
2024-12-04

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06735222 on ClinicalTrials.gov